Citigroup Inc Monte Rosa Therapeutics, Inc. Transaction History

Citigroup Inc

$169 Billion
Q3 2024

A detailed history of Citigroup Inc transactions in Monte Rosa Therapeutics, Inc. stock. As of the latest transaction made, Citigroup Inc holds 30,103 shares of GLUE stock, worth $212,226. This represents 0.0% of its overall portfolio holdings.

Number of Shares

30,103

Previous 9,538 215.61%

Holding current value

$212,226

Previous $35,000 354.29%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	$3.59 - $6.97 $73,828 - $143,338	20,565 Added 215.61%	30,103 $159,000
Q2 2024 Aug 12, 2024	BUY	$3.38 - $7.86 $12,303 - $28,610	3,640 Added 61.72%	9,538 $35,000
Q1 2024 May 10, 2024	BUY	$4.26 - $8.46 $6,390 - $12,690	1,500 Added 34.11%	5,898 $41,000
Q4 2023 Feb 09, 2024	BUY	$2.5 - $5.93 $9,227 - $21,887	3,691 Added 522.07%	4,398 $24,000
Q3 2023 Nov 09, 2023	SELL	$4.78 - $7.22 $49,095 - $74,156	-10,271 Reduced 93.56%	707 $3,000
Q2 2023 Aug 10, 2023	BUY	$4.53 - $8.4 $45,023 - $83,487	9,939 Added 956.59%	10,978 $75,000
Q1 2023 May 11, 2023	SELL	$5.95 - $8.21 $1,790 - $2,471	-301 Reduced 22.46%	1,039 $8,000
Q4 2022 Feb 09, 2023	SELL	$6.71 - $9.72 $1,140 - $1,652	-170 Reduced 11.26%	1,340 $10,000
Q3 2022 Nov 10, 2022	SELL	$7.17 - $12.16 $12,009 - $20,368	-1,675 Reduced 52.59%	1,510 $12,000
Q2 2022 Aug 10, 2022	BUY	$6.15 - $14.99 $4,243 - $10,343	690 Added 27.66%	3,185 $31,000
Q1 2022 May 12, 2022	SELL	$10.36 - $20.41 $23,910 - $47,106	-2,308 Reduced 48.05%	2,495 $35,000
Q4 2021 Feb 10, 2022	BUY	$16.28 - $27.15 $56,686 - $94,536	3,482 Added 263.59%	4,803 $98,000
Q3 2021 Nov 10, 2021	BUY	$18.59 - $42.21 $24,557 - $55,759	1,321 New	1,321 $29,000

Others Institutions Holding GLUE

# of Institutions

Shares Held

43.9M

Call Options Held

141K

Put Options Held

31.2K

View Full List

About Monte Rosa Therapeutics, Inc.

Ticker GLUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,713,900
Market Cap $329M
Description
Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing prot...

More about GLUE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Account